TNF, TGF-Β AND Р53 EXPRESSION IN CELLS OF CISPLATIN SENSITIVE AND RESISTANT OVARIAN CARCINOMA
Relationship was studied between the expression levels of TNF, TGF-β, and р53 in samples from ovarian carcinoma (OC) and clinical response of the tumor to cisplatin-based chemotherapy (CT). The growing media of primary OC cell cultures clinically resistant to CT showed significantly higher TNF levels (0,79 ± 0,13 ng/ml) compared to the media of tumor cell cultures sensitive to CT (0,35 ± 0,08 ng/ml; р < 0.05). TGF-β expression in the OC samples clinically sensitive and resistant to CT was higher in the group of CT-sensitive tumors (4,60 ± 1,20 ng/ml) and decreased in the group of resistant tumors (3,76 ± 0,90 ng/ml). The TNF expression level in OC after 3 cycles of neoadjuvant CT was higher (0,54 ± 0,12 ng/ml) compared to primary operated patients (0,31 ± 0,08 ng/ml). Samples of primary operated OC showed a TGF-β level of 5,45 ± 0,91 ng/ml, while samples of tumors from patients who underwent both CT and surgery showed a TGF-β level of 3,72 ± 1,2 ng/ml. Tumor samples from patients with clinically CT-resistant OC showed higher levels of р53 associated with the increased TNF expression in tumors. These findings show the role of TNF in the maintenance of OC resistance to CT and can be a basis for the development of treatment approaches with the use of TNF inhibitors with the view to prevent OC resistance to cisplatin.